Bleeding diathesis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 57: Line 57:
# Acquired Inhibitors of Coagulation Factors
# Acquired Inhibitors of Coagulation Factors


== Differential Diagnosis ==
== Differentiating Bleeding Disorders from Other Diseases ==
Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.  
Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.  


These features have discussed in the below table:
These features have discussed in the below table:
{|  
{|  
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-category
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Diseases
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
Line 76: Line 76:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Platelet count
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding time (BT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Prothrombin time (PT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Activated partial thromboplastin time (aPTT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Thrombin time (TT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
|-
|-
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span><ref name="pmid21325604">{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |date=April 2011 |pmid=21325604 |doi=10.1182/blood-2010-08-302984 |url=}}</ref><ref name="pmid26906627">{{cite journal |vauthors=Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP |title=Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection |journal=Lancet |volume=387 |issue=10022 |pages=939–940 |date=March 2016 |pmid=26906627 |doi=10.1016/S0140-6736(16)00502-X |url=}}</ref><ref name="pmid25600600">{{cite journal |vauthors=Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J |title=Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications |journal=J. Clin. Virol. |volume=63 |issue= |pages=32–5 |date=February 2015 |pmid=25600600 |doi=10.1016/j.jcv.2014.12.005 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* History of prior infection
* History of prior infection
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]] <ref name="pmid25134884">{{cite journal |vauthors=Kam T, Alexander M |title=Drug-induced immune thrombocytopenia |journal=J Pharm Pract |volume=27 |issue=5 |pages=430–9 |date=October 2014 |pmid=25134884 |doi=10.1177/0897190014546099 |url=}}</ref><ref name="pmid23461497">{{cite journal |vauthors=Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L |title=[Incidence of drug-induced thrombocytopenia in hospitalized patients] |language=Spanish; Castilian |journal=Farm Hosp |volume=37 |issue=1 |pages=27–34 |date=2013 |pmid=23461497 |doi=10.7399/FH.2013.37.1.42 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]]  
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
*History of [[Medication|medications]] such as:
*History of [[Medication|medications]] such as:
Line 112: Line 112:
** [[Linezolid]]  
** [[Linezolid]]  
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 119: Line 119:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span><ref name="pmid25629757">{{cite journal |vauthors=Warkentin TE, Safyan EL, Linkins LA |title=Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages |journal=N. Engl. J. Med. |volume=372 |issue=5 |pages=492–4 |date=January 2015 |pmid=25629757 |doi=10.1056/NEJMc1414161 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* [[Thrombosis]]
* [[Thrombosis]]
Line 136: Line 136:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span><ref name="pmid8857953">{{cite journal |vauthors=Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J |title=Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP) |journal=Br. J. Haematol. |volume=95 |issue=1 |pages=145–52 |date=October 1996 |pmid=8857953 |doi= |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* History of prior [[infection]] or no history
* History of prior [[infection]] or no history
Line 152: Line 152:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span><ref name="pmid27025194">{{cite journal |vauthors=Johnson B, Fletcher SJ, Morgan NV |title=Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan |journal=Platelets |volume=27 |issue=6 |pages=519–25 |date=September 2016 |pmid=27025194 |pmc=5000870 |doi=10.3109/09537104.2016.1148806 |url=}}</ref><ref name="pmid30103613">{{cite journal |vauthors=Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M |title=Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia |journal=Clin. Appl. Thromb. Hemost. |volume= |issue= |pages=1076029618790696 |date=August 2018 |pmid=30103613 |doi=10.1177/1076029618790696 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 168: Line 168:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span><ref name="pmid30220931">{{cite journal |vauthors=Knöbl P |title=Thrombotic thrombocytopenic purpura |journal=Memo |volume=11 |issue=3 |pages=220–226 |date=2018 |pmid=30220931 |doi=10.1007/s12254-018-0429-6 |url=}}</ref><ref name="pmid26386489">{{cite journal |vauthors=Mannucci PM, Cugno M |title=The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring |journal=Thromb. Res. |volume=136 |issue=5 |pages=851–4 |date=November 2015 |pmid=26386489 |doi=10.1016/j.thromres.2015.09.007 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span>
| align="left" style="background:#F5F5F5;" | History of:
| align="left" style="background:#F5F5F5;" | History of:
*[[Cancer]]
*[[Cancer]]
Line 190: Line 190:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span><ref name="pmid24365375">{{cite journal |vauthors=Webster K, Schnitzler E |title=Hemolytic uremic syndrome |journal=Handb Clin Neurol |volume=120 |issue= |pages=1113–23 |date=2014 |pmid=24365375 |doi=10.1016/B978-0-7020-4087-0.00075-9 |url=}}</ref><ref name="pmid25845294">{{cite journal |vauthors=Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P |title=Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome |journal=Pathol. Biol. |volume=63 |issue=3 |pages=136–43 |date=June 2015 |pmid=25845294 |doi=10.1016/j.patbio.2015.03.001 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span>
| align="left" style="background:#F5F5F5;" |History of:
| align="left" style="background:#F5F5F5;" |History of:
* [[Infections]]
* [[Infections]]
Line 212: Line 212:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
Line 235: Line 251:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal or ↑
| align="center" style="background:#F5F5F5;" | Nl or ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 255: Line 271:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Rare
| align="center" style="background:#F5F5F5;" | Rare
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* AR inheritance
* AR inheritance
Line 265: Line 281:
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]<ref name="pmid30077511">{{cite journal |vauthors=Dupuis A, Gachet C |title=Inherited platelet disorders : Management of the bleeding risk |journal=Transfus Clin Biol |volume=25 |issue=3 |pages=228–235 |date=September 2018 |pmid=30077511 |doi=10.1016/j.tracli.2018.07.003 |url=}}</ref><ref name="pmid29227167">{{cite journal |vauthors=Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H |title=Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach |journal=Platelets |volume=29 |issue=4 |pages=347–356 |date=June 2018 |pmid=29227167 |doi=10.1080/09537104.2017.1386297 |url=}}</ref>
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 274: Line 290:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal/
| align="center" style="background:#F5F5F5;" | Nl or
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* AR inheritance
* AR inheritance
Line 285: Line 301:
* Ristocetin - no aggregation
* Ristocetin - no aggregation
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid23527934">{{cite journal |vauthors=Wang YQ, Cui YX, Feng J |title=[Clinical phenotype and gene diagnostic analysis of Omenn syndrome] |language=Chinese |journal=Zhonghua Er Ke Za Zhi |volume=51 |issue=1 |pages=64–8 |date=January 2013 |pmid=23527934 |doi= |url=}}</ref><ref name="pmid27340577">{{cite journal |vauthors=Patil RB, Shanmukhaiah C, Jijina F, Bamborde S, Wasekar N, Toshniwal M, Mohite A, Patil V |title=Wiskott-Aldrich Syndrome Presenting with JMML-Like Blood Picture and Normal Sized Platelets |journal=Case Rep Hematol |volume=2016 |issue= |pages=8230786 |date=2016 |pmid=27340577 |pmc=4906177 |doi=10.1155/2016/8230786 |url=}}</ref><ref name="pmid29348920">{{cite journal |vauthors=Kaneko R, Yamamoto S, Okamoto N, Akiyama K, Matsuno R, Toyama D, Hoshino A, Imai K, Isoyama K |title=Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection |journal=SAGE Open Med Case Rep |volume=6 |issue= |pages=2050313X17753788 |date=2018 |pmid=29348920 |pmc=5768273 |doi=10.1177/2050313X17753788 |url=}}</ref><ref name="pmid19084106">{{cite journal |vauthors=Ozcan E, Notarangelo LD, Geha RS |title=Primary immune deficiencies with aberrant IgE production |journal=J. Allergy Clin. Immunol. |volume=122 |issue=6 |pages=1054–62; quiz 1063–4 |date=December 2008 |pmid=19084106 |doi=10.1016/j.jaci.2008.10.023 |url=}}</ref>
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 294: Line 310:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
* In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
* In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
|-
|-
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |[[Platelet storage pool deficiency|Platelet storage pool disorder (SPD)]]:  
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |Platelet storage pool disorder:  
*[[Hermansky-Pudlak syndrome]]
*[[Hermansky-Pudlak syndrome]]
*[[Chediak-Higashi syndrome]]
*[[Chediak-Higashi syndrome]]
*[[Gray platelet syndrome]]
*[[Gray platelet syndrome]]
| align="center" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
* [[Hairy cell leukemia]]
* [[Hairy cell leukemia]]
Line 317: Line 333:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* AD inheritance
* AD inheritance
* Abnormalities of platelet granule formation
* AbNlities of platelet granule formation
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
| align="left" style="background:#F5F5F5 |
| align="left" style="background:#F5F5F5 " |
* [[Chronic renal failure pathophysiology|Uremia]]
* [[Chronic renal failure pathophysiology|Uremia]]
* [[Cardiopulmonary bypass]]
* [[Cardiopulmonary bypass]]
Line 335: Line 351:
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | Normal/
| align="center" style="background:#F5F5F5;" | Nl or
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid16985174">{{cite journal |vauthors=Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I |title=Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) |journal=Blood |volume=109 |issue=1 |pages=112–21 |date=January 2007 |pmid=16985174 |doi=10.1182/blood-2006-05-020784 |url=}}</ref><ref name="pmid9579642">{{cite journal |vauthors=Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ |title=PFA-100 system: a new method for assessment of platelet dysfunction |journal=Semin. Thromb. Hemost. |volume=24 |issue=2 |pages=195–202 |date=1998 |pmid=9579642 |doi=10.1055/s-2007-995840 |url=}}</ref><ref name="pmid258585642">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span>  
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Easy bruising
* Easy bruising
Line 356: Line 372:
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
* Acute febrile illnesses
* Acute febrile illnesses
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
* [[Monoclonal gammopathy|Monoclonal gammopathies]]
* [[Monoclonal gammopathy|Monoclonal gammopathies]]
* Certain pathogens, such as the rickettsiae causing [[Rocky Mountain spotted fever]]
* [[Rocky Mountain spotted fever]]
* [[Vitamin C]] deficiency
* [[Vitamin C deficiency]]
* [[Cushing's syndrome|Cushing’s syndrome]]  
* [[Cushing's syndrome|Cushing’s syndrome]]  
* Chronic [[glucocorticoid]] therapy  
* Chronic [[glucocorticoid]] therapy  
* [[Ageing|Aging]] 
* [[Vasculitis]] such as Henoch-Schönlein Purpura
* [[Vasculitis]] such as Henoch-Schönlein,
| align="left" style="background:#F5F5F5;" |
|
* History of the underlying disease
* History of the underlying disease.
| align="center" style="background:#F5F5F5;" |−
|−
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>+/-</nowiki>
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl or
|↑/Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |−
|<nowiki>-</nowiki>
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" align="left" style="background:#DCDCDC;" |
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Ehlers-Danlos syndrome]]
* [[Ehlers-Danlos syndrome]]
* [[Pseudoxanthoma elasticum]]
* [[Pseudoxanthoma elasticum]]
* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
|
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+/-</nowiki>
| align="center" style="background:#F5F5F5;" |±
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑/Normal
| align="center" style="background:#F5F5F5;" |Nl or
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders<ref name="pmid29027765">{{cite journal |vauthors=Karimi M, Peyvandi F, Naderi M, Shapiro A |title=Factor XIII deficiency diagnosis: Challenges and tools |journal=Int J Lab Hematol |volume=40 |issue=1 |pages=3–11 |date=February 2018 |pmid=29027765 |doi=10.1111/ijlh.12756 |url=}}</ref><ref name="pmid27590165">{{cite journal |vauthors=Peyvandi F, Garagiola I, Biguzzi E |title=Advances in the treatment of bleeding disorders |journal=J. Thromb. Haemost. |volume=14 |issue=11 |pages=2095–2106 |date=November 2016 |pmid=27590165 |doi=10.1111/jth.13491 |url=}}</ref><ref name="pmid28966616">{{cite journal |vauthors=Bender L, Weidmann H, Rose-John S, Renné T, Long AT |title=Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis |journal=Front Immunol |volume=8 |issue= |pages=1115 |date=2017 |pmid=28966616 |pmc=5605561 |doi=10.3389/fimmu.2017.01115 |url=}}</ref><ref name="pmid28966616" /><ref name="pmid27380557">{{cite journal |vauthors=Schmaier AH |title=Antithrombotic potential of the contact activation pathway |journal=Curr. Opin. Hematol. |volume=23 |issue=5 |pages=445–52 |date=September 2016 |pmid=27380557 |pmc=5148823 |doi=10.1097/MOH.0000000000000271 |url=}}</ref><ref name="pmid26565070">{{cite journal |vauthors=Schmaier AH |title=The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities |journal=J. Thromb. Haemost. |volume=14 |issue=1 |pages=28–39 |date=January 2016 |pmid=26565070 |doi=10.1111/jth.13194 |url=}}</ref><ref name="pmid20580091">{{cite journal |vauthors=Kaplan AP, Ghebrehiwet B |title=The plasma bradykinin-forming pathways and its interrelationships with complement |journal=Mol. Immunol. |volume=47 |issue=13 |pages=2161–9 |date=August 2010 |pmid=20580091 |doi=10.1016/j.molimm.2010.05.010 |url=}}</ref><ref name="pmid22185738">{{cite journal |vauthors=Zuraw BL, Christiansen SC |title=Pathophysiology of hereditary angioedema |journal=Am J Rhinol Allergy |volume=25 |issue=6 |pages=373–8 |date=2011 |pmid=22185738 |doi=10.2500/ajra.2011.25.3661 |url=}}</ref><ref name="pmid23629422">{{cite journal |vauthors=Quail MT |title=Prekallikrein deficiency |journal=J Pediatr Oncol Nurs |volume=30 |issue=4 |pages=198–204 |date=2013 |pmid=23629422 |doi=10.1177/1043454213487436 |url=}}</ref><ref name="pmid27894217">{{cite journal |vauthors=Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, Asadi M, Jalalvand M, Shamsizadeh M |title=Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran |journal=Hematology |volume=22 |issue=4 |pages=224–230 |date=May 2017 |pmid=27894217 |doi=10.1080/10245332.2016.1263007 |url=}}</ref><ref name="pmid29483100">{{cite journal |vauthors=Maas C, Renné T |title=Coagulation factor XII in thrombosis and inflammation |journal=Blood |volume=131 |issue=17 |pages=1903–1909 |date=April 2018 |pmid=29483100 |doi=10.1182/blood-2017-04-569111 |url=}}</ref>
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency<ref name="pmid29844251">{{cite journal |vauthors=Tiscia GL, Margaglione M |title=Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders |journal=Int J Mol Sci |volume=19 |issue=6 |pages= |date=May 2018 |pmid=29844251 |pmc=6032319 |doi=10.3390/ijms19061597 |url=}}</ref>
<ref name="pmid28966616" />
! style="padding: 5px 5px; background: #DCDCDC;" |Different types of the [[fibrinogen]] disorders:
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency
! colspan="2" align="left" style="padding: 5px 5px; background: #DCDCDC;" |
Different types of the [[fibrinogen]] disorders:
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
Line 422: Line 455:
* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
* [[Fibrinogen#Congenital hypodysfibrinogenemia|Congenital hypodysfibrinogenemia]][[Fibrinogen#Cryofibrinogenemia|Cryofibrinogenemia]]
| align="left" style="background:#F5F5F5;" |
* [[Fibrinogen#Acquired hypofibrinogenemia|Acquired hypofibrinogenemia]]
|
* [[Epistaxis]]
* [[Epistaxis]]
* Easy [[Bruise|bruising]]
* Easy [[Bruise|bruising]]
Line 432: Line 463:
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* Bleeding after [[dental surgery]] or tooth extraction
* Bleeding after [[dental surgery]] or tooth extraction
* Abnormal bleeding during or after injury, surgery, or childbirth
* AbNl bleeding during or after injury, surgery, or childbirth
 
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
* [[Cerebral hemorrhage]]
* [[Cerebral hemorrhage]]
* [[Thrombosis]]
* [[Thrombosis]]
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +/-
| align="center" style="background:#F5F5F5;" |±
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|
| align="left" style="background:#F5F5F5;" |
* Impaired fibrin cross linking or clot dissolution.
* Impaired fibrin cross-linking or clot dissolution
 
* Mild or severe bleeding idepend on levels of functional fibrinogen
* The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen.  The age of onset is also variable, with earlier onset in those with more severe deficiency.
* Variable age of onset
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Easy [[bruising]]
* [[Epistaxis]]
* [[Epistaxis]]
* Soft-tissue hemorrhage
* Soft-tissue hemorrhage
Line 463: Line 508:
* [[Hemarthrosis]]
* [[Hemarthrosis]]
* [[Intracranial hemorrhage|Intracranial]] bleeding
* [[Intracranial hemorrhage|Intracranial]] bleeding
|
| align="center" style="background:#F5F5F5;" | −
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|Normal
| align="center" style="background:#F5F5F5;" | Nl
|↑
| align="center" style="background:#F5F5F5;" | ↑
|↑
| align="center" style="background:#F5F5F5;" | ↑
|↑
| align="center" style="background:#F5F5F5;" | ↑
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
|
| align="left" style="background:#F5F5F5;" |  
* Excessive bruising with minor injuries
* Excessive bruising with minor injuries
* [[Epistaxis]]
* [[Epistaxis]]
Line 484: Line 529:
* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
* [[Pulmonary hemorrhage]]  
* [[Pulmonary hemorrhage]]  
|
| align="center" style="background:#F5F5F5;" | −
|_
| align="center" style="background:#F5F5F5;" | −
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
| align="center" style="background:#F5F5F5;" |
* The severity of bleeding related to the degree of factor V deficiency
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Easy [[Bruise|bruising]]
* Easy [[Bruise|bruising]]
* Mucosal bleeding
* Mucosal bleeding
Line 505: Line 551:
* Soft tissue hematomas
* Soft tissue hematomas
* [[Thrombosis]]  
* [[Thrombosis]]  
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|
| align="center" style="background:#F5F5F5;" |
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy  
| align="left" style="background:#F5F5F5;" |
* Thrombosis in inherited factor VII deficiency
* Treatment with the administration of factor VII replacement therapy  
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Prolonged bleeding following circumcision
* Prolonged bleeding following circumcision
* Easy [[Bruise|bruising]]
* Easy [[Bruise|bruising]]
* [[Hematuria]]
* [[Hematuria]]
Line 531: Line 578:
* Intracranial bleeding
* Intracranial bleeding
* Hemarthroses
* Hemarthroses
|
| align="center" style="background:#F5F5F5;" |
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
| +
| align="center" style="background:#F5F5F5;" | +
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
|
| align="left" style="background:#F5F5F5;" |
* Majority,asymptomatic
* Asymptomatic
* Recurrent miscarriages
* Recurrent miscarriages
* Painful leg ulcers
* Painful leg ulcers
|
| align="center" style="background:#F5F5F5;" |
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
|
| align="left" style="background:#F5F5F5;" |
* Possibility of positive family history of bleeding
* Positive family history of bleeding
|
| align="center" style="background:#F5F5F5;" |
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|-
|-
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
|
| align="left" style="background:#F5F5F5;" |
* Possibility of positive family history of bleeding
* Positive family history of bleeding
|
| align="center" style="background:#F5F5F5;" |
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|_
| align="center" style="background:#F5F5F5;" |−
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="center" style="background:#F5F5F5;" |
|-
|-
! colspan="2" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! style="padding: 5px 5px; background: #DCDCDC;" |Types:
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |
* Sub unit A mutation disease (more common)
* Sub unit A mutation disease (more common)
* Sub unit B mutation disease
* Sub unit B mutation disease
|
| align="left" style="background:#F5F5F5;" |
* Possibility of positive family history of bleeding
* Positive family history of bleeding
| -/+
| align="center" style="background:#F5F5F5;" |±
| -/+
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" |±
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal/
| align="center" style="background:#F5F5F5;" |Nl or
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|
| align="left" style="background:#F5F5F5;" |
* Impaired fibrin cross linking or clot dissolution
* Impaired fibrin cross-linking or clot dissolution
* The severity of factor XIII deficiency bleeds can be different in different patients  
* The severity of factor XIII deficiency bleeds can be different in different patients  
|-
|-
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid94489952">{{cite journal |vauthors=Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C |title=Rheumatic manifestations of hematologic disorders |journal=Curr Opin Rheumatol |volume=10 |issue=1 |pages=86–90 |date=January 1998 |pmid=9448995 |doi= |url=}}</ref><ref name="pmid16551972">{{cite journal |vauthors=Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR |title=Bleeding in carriers of hemophilia |journal=Blood |volume=108 |issue=1 |pages=52–6 |date=July 2006 |pmid=16551972 |doi=10.1182/blood-2005-09-3879 |url=}}</ref><ref name="pmid25059285">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref><ref name="pmid11307831">{{cite journal |vauthors=White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J |title=Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis |journal=Thromb. Haemost. |volume=85 |issue=3 |pages=560 |date=March 2001 |pmid=11307831 |doi= |url=}}</ref><ref name="pmid24026910">{{cite journal |vauthors=Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G |title=Problems and solutions in laboratory testing for hemophilia |journal=Semin. Thromb. Hemost. |volume=39 |issue=7 |pages=816–33 |date=October 2013 |pmid=24026910 |doi=10.1055/s-0033-1356573 |url=}}</ref><ref name="pmid250592852">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref>
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]
 
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
|
| align="left" style="background:#F5F5F5;" |
* Eeasy [[Bruise|bruising]]
* Eeasy [[Bruise|bruising]]
* Inadequate clotting in [[trauma]] or mild injury
* Inadequate clotting in [[trauma]] or mild injury
Line 625: Line 687:
* [[Epistaxis]]
* [[Epistaxis]]
* [[Gingival bleeding]]
* [[Gingival bleeding]]
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| +
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
|
| align="left" style="background:#F5F5F5;" |
* Neonatal bleeding
* Neonatal bleeding
* Trauma-related soft-tissue hemorrhage
* Trauma-related soft tissue hemorrhage
* [[Hemarthrosis]]   
* [[Hemarthrosis]]   
* [[Hematoma|Hematomas]]  
* [[Hematoma|Hematomas]]  
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
|
| align="left" style="background:#F5F5F5;" |
* Family history  
* Positive family history  
* Bleeding after surgery or injury
* Bleeding after surgery or injury
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
| -
| align="center" style="background:#F5F5F5;" |−
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|Rare
| align="center" style="background:#F5F5F5;" |Rare
|Rare
| align="center" style="background:#F5F5F5;" |Rare
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
| -
| align="center" style="background:#F5F5F5;" |−
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Subcategory
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid30008620">{{cite journal |vauthors=Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M |title=Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy |journal=Thromb J |volume=16 |issue= |pages=14 |date=2018 |pmid=30008620 |pmc=6040080 |doi=10.1186/s12959-018-0168-2 |url=}}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
! style="padding: 5px 5px; background: #DCDCDC;" |
| align="left" style="background:#F5F5F5;" |
* [[Trauma]]
* [[Trauma]]
* Burn  
* [[Burn]]
* [[Crush injury]]
* [[Crush injury]]
* [[Sepsis]]
* [[Sepsis]]
Line 684: Line 762:
* Obstetric complication: abruption, amniotic fluid embolism
* Obstetric complication: abruption, amniotic fluid embolism
* [[Hemolytic anemia]]
* [[Hemolytic anemia]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|↓
| align="center" style="background:#F5F5F5;" |↓
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal
| align="center" style="background:#F5F5F5;" |Nl
| -
| align="center" style="background:#F5F5F5;" |−
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid26314836">{{cite journal |vauthors=Shiraishi E, Iijima H, Shinzaki S, Nakajima S, Inoue T, Hiyama S, Kawai S, Araki M, Yamaguchi T, Hayashi Y, Fujii H, Nishida T, Tsujii M, Takehara T |title=Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis |journal=J. Gastroenterol. |volume=51 |issue=4 |pages=346–56 |date=April 2016 |pmid=26314836 |doi=10.1007/s00535-015-1112-x |url=}}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]
! style="padding: 5px 5px; background: #DCDCDC;" |
| align="left" style="background:#F5F5F5;" |
* Bleeding after trauma
* Bleeding after trauma
* [[Epistaxis]]
* [[Epistaxis]]
Line 708: Line 786:
* Oozing from venipuncture sites  
* Oozing from venipuncture sites  
* Easy [[Bruise|bruisability]]
* Easy [[Bruise|bruisability]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
| -
| align="center" style="background:#F5F5F5;" |
| +
| align="center" style="background:#F5F5F5;" |+
| +
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" |+
|Normal
| align="center" style="background:#F5F5F5;" |Nl
|↑
| align="center" style="background:#F5F5F5;" |
|↑
| align="center" style="background:#F5F5F5;" |↑
|Normal or mildly prolonged
| align="center" style="background:#F5F5F5;" |Nl or mildly prolonged
|Normal
| align="center" style="background:#F5F5F5;" |Nl
| -
| align="center" style="background:#F5F5F5;" |
|}
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:<ref name="pmid258585643">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
 
{|
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of VWD
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of factor deficiency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Prevalence
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inheritance pattern
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |VWF activity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RIPA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Factor VIII
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Type 1
| align="center" style="background:#F5F5F5;" | Quantitative/ partial
| align="center" style="background:#F5F5F5;" | 60-70%
| align="center" style="background:#F5F5F5;" | AD
| align="left" style="background:#F5F5F5;" |
* Bleeding severity mild to severe
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
|-
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2
! align="center" style="background:#DCDCDC;" |2A<ref name="pmid1537829">{{cite journal |vauthors=Lyons SE, Bruck ME, Bowie EJ, Ginsburg D |title=Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations |journal=J. Biol. Chem. |volume=267 |issue=7 |pages=4424–30 |date=March 1992 |pmid=1537829 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | 10%
| align="center" style="background:#F5F5F5;" | AD/AR
| align="left" style="background:#F5F5F5;" |
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
! align="center" style="background:#DCDCDC;" |2B
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | 5%
| align="center" style="background:#F5F5F5;" | AD
| align="left" style="background:#F5F5F5;" |
* [[Thrombocytopenia]]
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | N or
|-
! align="center" style="background:#DCDCDC;" |2M
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | <1%
| align="center" style="background:#F5F5F5;" | AD/AR
| align="left" style="background:#F5F5F5;" |
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | N or ↓
|-
! align="center" style="background:#DCDCDC;" |2N
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | <1%
| align="center" style="background:#F5F5F5;" | AR
| align="left" style="background:#F5F5F5;" |
* Clinically similar to [[hemophilia A]] with [[joint]], [[soft tissue]], [[urinary]] [[bleeding]]
| align="center" style="background:#F5F5F5;" | N
| align="center" style="background:#F5F5F5;" | N
| align="center" style="background:#F5F5F5;" | ↓
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Type 3
| align="center" style="background:#F5F5F5;" | Complete deficiency
| align="center" style="background:#F5F5F5;" | 1-2%
| align="center" style="background:#F5F5F5;" | AR
| align="left" style="background:#F5F5F5;" |
* Clinically similar to [[hemophilia A]] with [[joint]] and [[soft tissue]] [[bleeding]]
* Severe [[mucosal bleeding]]
| align="center" style="background:#F5F5F5;" | Absent
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Low, 1-10%
|}
|}
For more information on Von Willebrand disease, click [[ von willebrand disease | here]].


==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 17:20, 19 October 2018


Bleeding diathesis main page

Overview

Classification

Differential Diagnosis

Platelet disorders
Immune Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Hemolytic Uremic Syndrome
Thrombocytosis
Von Willebrand Disease
Coagulation disorders
Fibrinogen deficiency
Prothrombin deficiency
Factor V deficiency
Factor VII deficiency
Factor VIII deficiency
Factor IX deficiency
Factor X deficiency
Factor XI deficiency
Factor XII deficiency
High-molecular-weight kininogen deficiency
Prekallikrein deficiency
Factor XIII deficiency
Hemophilia
Rare diseases
Disseminated Intravascular Coagulation
Vitamin K Deficiency

Different types of Von-Willebrand diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Nazia Fuad M.D., Sogand Goudarzi, MD [3]

Synonyms and keywords: Hypocoagulopathy; Bleeding disorders.

Overview

Bleeding diathesis is susceptibility to bleed due to coagulopathy disorders or platelets disorders. These diseases can occur due to a disorder of homeostasis, localized process (tissue injury), or medications. Bleeding diathesis can be resulted from vessel wall injury, platelet disorders, and coagulation factor disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. Platelet disorders mostly have skin manifestations such as petechiae, and ecchymoses. In order to find the cause of hypo-coagulopathy; there are established laboratory tests, such as peripheral blood smear, platelet count and platelet function analysis, coagulation factor deficiencies and inhibitors, fibrinolysis tests (eg. D-dimer level), bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are CBC, PT, PTT, BT, and TT.[1]

Classification

Disorders of hemostasis can be classified into two main categories: platelet disorders, and disorders of coagulation. Each category can be further classified as bellow:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abnormal hemostasis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

•Patient history-sign & symptom: Deep soft tissue bleeding Mucocutaneus bleeding
•Screen test CBBC-plt-PT&PTT-BT-TT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hx of deep soft tissue bleeding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hx of mucocotaneus bleeding
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulopathy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plt disorder
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family history
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal plt count
 
 
Low plt count
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(+)
•Inherited coagulpathy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(-)
•Aquired coagulopathy
 
 
 
 
 
 
Functional Plt disorder
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑Plt
•Hemophillia
•VWD
•FactorVIII or IX deficiency
 
↑PT
• Factor VII deficiensy
 
↑PT&↑PTT
•Fibrinogen deficiency
•FactorII deficiency
•FactorV deficiency
•FactorX deficiency
 
 
↑PTT
•Factor inhibitor
•Anti phospholipid A6syndrome
 
↑PT
•Factor inhibitor
•VitK deficiency
•Liver disease
 
↑PT&↑PTT
•Factor inhibit
•DIC
•Liver failure
•late stage of VitK deficincy
 
↑Afibrinogenia
•Heparin inhibitor
•Direct thrombin inhibitor
 
 
 
 
Abnormal solobity
•FactorXIII deficincy
•Cross-linkin inhibitor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not corrected with mixing with NL plasma
 
 
 
 
 
 
 
 
HX(+)
 
HX(-)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

•Factor inhibitors
•Lupus anti coagulant
•DIC
•Heparin or direct thrombin inhibitors
 
 
 
 
 
 
 
 
Congenital
 
Acquired
 
 
 
 
 

Platelet disorders:

  1. Thrombocytopenia: platelet count less than 150,000 per mm3
  2. Thromobcytosis: platelet count more than 450,000 per mm3
  3. Qualitative Disorders of Platelet function such as Von Willebrand Disease, inherited or acquired functional disorders.

Coagulation disorders

  1. Vessel wall disorders: Endothelial cells are lining entire vessel walls all over the body. Endothelium is an active layer responsible for inflammatory responses, angiogenesis and blood cell interactions. Endothelial cells have a very important role in hemostasis and they are regulating blood fluidity by the balance of antithrombotic/prothrombotic and vasodilatory/vasoconstrictor effects.
  2. Coagulation factor disorders:
  3. Disseminated Intravascular Coagulation
  4. Vitamin K Deficiency
  5. Coagulation Disorders Associated with Liver Failure
  6. Acquired Inhibitors of Coagulation Factors

Differentiating Bleeding Disorders from Other Diseases

Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.

These features have discussed in the below table:

Category Subcategory Disease History Clinical manifestation Laboratory testing Comments
Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia
  • History of prior infection
+ + + + + + Nl Nl Nl
Medications-Induced thrombocytopenia + + + + + + Nl Nl Nl Most important part of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia + + + + + + Nl Nl For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura (ITP) + + + + + + Nl Nl Nl
Inherited Thrombocytopenia
  • Positive family history
+ + + + + + Nl Nl Nl
Thrombotic Thrombocytopenic Purpura (TTP) History of: + + + + + + Nl Nl Nl
Hemolytic Uremic Syndrome History of: + + + + + + Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Thromobcytosis Iron deficiency anemia

Inflammatory diseases

Splenectomy

Essential thrombocytosis

± ± Nl or ↑ Nl Nl Nl
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + + Rare Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Wiskott-Aldrich syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • Anti-WASP antibody can be used to detect presence or absence of WAS protein
  • In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
Platelet storage pool disorder: + + + + Nl or ↓ Nl Nl Nl
  • AD inheritance
  • AbNlities of platelet granule formation
Acquired Disorders of Platelet Function + + + + ± ± Nl or ↓ Nl Nl Nl
Von Willebrand Disease + + + + ± ± Nl Nl See the table below for the details about different types.
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease
+ + ± Nl Nl or ↑ Nl Nl Nl
Inherited Disorders of the Vessel Wall
  • Positive family history
+ + ± Nl Nl or ↑ Nl Nl Nl
Coagulation factor disorders

[2]

Fibrinogen deficiency

Different types of the fibrinogen disorders:

+ + ± + Nl
  • Impaired fibrin cross-linking or clot dissolution
  • Mild or severe bleeding idepend on levels of functional fibrinogen
  • Variable age of onset
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Prothrombin deficiency + + + + + Nl Nl
Factor V deficiency + + + + Nl Nl
  • The severity of bleeding related to the degree of factor V deficiency
Factor VII deficiency + + + Nl Nl Nl
  • Thrombosis in inherited factor VII deficiency
  • Treatment with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
  • Easy bruising
  • Hematuria
  • Menorrhagia
  • Abortion
  • Postpartum hemorrhage
  • Epistaxis
  • Pseudotumors
  • Intracranial bleeding
  • Hemarthroses
+ + + + + Nl Nl Nl
Factor XII deficiency
  • Asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
Nl Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
High molecular weight kininogen (HMWK) deficiency
  • Positive family history of bleeding
Nl Nl Nl Nl
Prekallikrein deficiency
  • Positive family history of bleeding
Nl Nl Nl Nl
Factor XIII deficiency
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Positive family history of bleeding
± ± ± ± ± ± Nl Nl Nl or ↑ Nl Nl
  • Impaired fibrin cross-linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia Type A deficiency + + + Nl Nl Nl Nl
Type B deficiency + + + Nl Nl Nl Nl
Type C deficiency
  • Positive family history
  • Bleeding after surgery or injury
+ Rare Rare Nl Nl Nl Nl
Subcategory Disease History Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT Comments
Rare diseases Disseminated Intravascular Coagulation + + + + + + Nl
Vitamin K Deficiency + + + + + Nl Nl or mildly prolonged Nl

References

  1. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL (September 2003). "Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice". Thromb. Haemost. 90 (3): 483–90. doi:10.1160/TH03-02-0111. PMID 12958618.